Background Dislocation complicates 1% to 5% of primary total hip arthroplasties (THAs). As a result, some surgeons consider dual-mobility articulations, which are usually used in the revision setting to decrease the likelihood of dislocation, as an option for primary THA. However, few studies have evaluated their use in this setting. Questions/purposes (1) What is the cup survivorship when the dual-mobility articulation is used in the setting of primary THA? (2) What are the clinical outcomes with this approach? (3) What are the radiographic outcomes? (4) What are the complications of dual-mobility articulations in primary THA? Methods Between 2011 and 2013, the five participating surgeons performed 495 cementless primary THAs. During that time, one of the five surgeons used dual-mobility articulations for all THAs, and the other four used it whenever the acetabular cup size was 52 mm or greater to enable a 28-mm head. Of the 495 patients, 453 (92%) were performed using this device. Smaller patients were treated with a standard THA. Of the 453 patients, a total of 43 One of the authors certifies that he (PMB) has received or may receive payments, during the study period, an amount of USD 100,000 to USD 1,000,000 from Stryker Orthopaedics (Mahwah, NJ, USA) and an amount of USD 10,000 to USD 100,000 from Joint Active Systems (Effingham, IL, USA). One of the authors certifies that he (SFH) has received or may receive payments, during the study period, an amount of USD 100,000 to USD 1,000,000 from Stryker Orthopaedics, less than USD 10,000 from Slack Inc (Thorofare, NJ, USA), an amount of USD 10,000 to USD 100,000 from Convatec, and less than USD 10,000 from Thieme Inc (New York, NY, USA). One of the authors certifies that he (ALM) has received or may receive payments, during the study period, an amount of USD 100,000 to USD 1,000,000 from Stryker Orthopaedics. One of the authors certifies that he (FRK) has received or may receive payments, during the study period, an amount of USD 100,000 to USD 1,000,000 from Stryker Orthopaedics and an amount of USD 10,000 to USD 100,000 from DJ Orthopedics (Vista, CA, USA). One of the authors certifies that he (MAM) has received or may receive payments, during the study period, an amount of USD 100,000 to USD 1,000,000 from Stryker Orthopaedics, an amount of USD 10,000 to USD 100,000 from DJ Orthopedics, an amount of USD 10,000 to USD 100,000 from Microport (Arlington, TN, USA), an amount of USD 10,000 to USD 100,000 from J&J (New Brunswick NJ, USA), an amount of USD 10,000 to USD 100,000 from Medical Compression Systems (Tel Aviv, Israel), an amount of USD 10,000 to USD 100,000 from OnGoing Care Solutions (Pinellas Park, FL, USA), an amount of USD 10,000 to USD 100,000 from Sage Products LLC (Cary, IL, USA), an amount of USD 10,000 to USD 100,000 from TissueGene (Rockville, MD, USA) an amount of USD 10,000 to USD 100,000 from Pacira Pharmaceuticals (Parsippany, NJ, USA), an amount of USD 10,000 to USD 100,000 from Merz (Frankfurt, Germany), and an amount of USD 10,000 ...